The fight over breast-cancer treatment with Roche's Avastin has come to a head: U.S. officials decided to revoke the drug's indication for breast cancer, and European Medicines Agency moved to restrict it for use with only one type of chemotherapy.
The decisions stand to cut more than $1 billion off Avastin's $6 billion in annual revenues, and they're sure to draw fire from folks who've been advocating for the drug.